Der Anaesthesist

, Volume 59, Issue 6, pp 566–574 | Cite as

Querschnittleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: Humanalbumin

Empfehlungen des wissenschaftlichen Beirats der Bundesärztekammer
Leitlinien und Empfehlungen


Humanalbumin (HA) ist mit Abstand die teuerste Möglichkeit zum Ausgleich eines Volumenmangels. Darüberhinaus kommt HA vielfach zum Ausgleich einer Hypoalbuminämie zum Einsatz. Angesichts zunehmend eingeschränkter finanzieller Resourcen stellt sich die Frage, inwieweit die Gabe von HA heute noch zu rechtfertigen ist. Der Beirat der Bundesärztekammer hat dazu kürzlich Querschnittleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten herausgegeben. Die Gabe von HA zur Therapie des Volumenmangels im perioperativen Bereich und beim Intensivpatienten wird generell nicht empfohlen, sondern es wird auf moderne kolloidale Volumenersatzmittel als sichere Alternativen verwiesen. Auch zum Volumenersatz bei Kindern wird HA nicht als Therapie der ersten Wahl empfohlen, da deutlich preisgünstigere Alternativen bestehen. Der Ausgleich einer Hypoalbuminämie mithilfe von HA in der Intensivmedizin wird ebenfalls nicht generell empfohlen. Ausnahmen hierzu könnten Patienten mit Leberzirrhose, spontan-bakterieller Peritonitis und ausgeprägter Aszitesentlastung sein, obwohl Vergleiche mit modernen kolloidalen Volumenersatzmitteln hierzu fehlen. Humanalbumin zur Verbesserung der Transportkapazität von Medikamenten und als Radikalenfänger bzw. zur Bindung toxischer Substanzen wird nicht empfohlen. Zusammenfassend lässt sich feststellen, dass gemäß den Empfehlungen des wissenschaftlichen Beirats der Bundesärztekammer die Gabe von HA sehr sorgsam zu überdenken ist.


Volumenmangel Hypoalbuminämie Kosten Empfehlungen Intensivmedizin Blutverlust 

Guidelines on therapy with blood components and plasma derivatives: human albumin

Recommendations of the scientific advisory board of the Medical Council


Human albumin (HA) is by far the most expensive option for volume replacement and correction of hypoalbuminemia but is still widely used. The value of HA in the clinical setting continues to be controversial and it remains unclear whether there is still a place for using such a high-priced substance in the present cost-consciousness climate. Thus the Medical Council has presented some recommendations with regard to blood and plasma products including HA. There appear to be no indications for HA to correct hypovolemia either perioperatively or in the intensive care setting including children and patients undergoing cardiac or liver surgery. For maintaining colloid oncotic pressure (COP) cheaper modern synthetic colloids can be alternatively given and the value of HA for correcting hypoalbuminemia is also not clearly justified. Some small uncontrolled studies have shown that only patients with liver cirrhosis, spontaneous bacterial peritonitis and massive ascites drainage may profit from HA. Theoretical benefits such as oxygen radical scavenging or binding of toxic substances are no indications for using HA as benefical clinical consequences have not yet been demonstrated. Experimental data from cell lines or animals must be viewed with skepticism because they do not mimic the clinical setting. According to the recommendations of the scientific advisory board of the Medical Council the use of HA should be considered very cautiously.


Volume replacement Hypoalbuminemia Costs Critical illness Blood loss Recommendations 



Der korrespondierende Autor weist auf folgende Beziehung/en hin: B. Braun, Fresenius-Kabi, Edwards, Baxter.


  1. 1.
    Alderson P, Bunn F, Lefebvre C et al (2004) Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 18:CD001208Google Scholar
  2. 2.
    Altman C, Bernard B, Roulot D et al (1998) Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 10:5–10PubMedCrossRefGoogle Scholar
  3. 3.
    Angeli P, Violpin R, Gerunda G et al (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690–1697PubMedCrossRefGoogle Scholar
  4. 4.
    Avorn J, Patel M, Levin R, Winkelmayer WC (2003) Hetastarch and bleeding complications after coronary artery surgery. Chest 124:1437–1442PubMedCrossRefGoogle Scholar
  5. 5.
    Boldt J (1997) Volumensubstitution in der perioperativen Phase unter besonderer Berücksichtigung der Kardiochirurgie. Infusionsther Transfusionsmed 24:92–98Google Scholar
  6. 6.
    Boldt J, Knothe C, Schindler E et al (1993) Volume replacement with hydroxyethyl starch solution in children. Br J Anaesth 70:661–665PubMedCrossRefGoogle Scholar
  7. 7.
    Boldt J, Papsdorf M (2008) Fluid management in burn patients: results from a European survey – more questions than answers. Burns 34:328–338PubMedCrossRefGoogle Scholar
  8. 8.
    Boldt J, Schöllhorn T, Mayer J et al (2006) The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery. Anesth Analg 103:191–199PubMedCrossRefGoogle Scholar
  9. 9.
    Bundesärztekammer auf Empfehlung ihres Wissenschaftlichen Beirats (2009) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. überarb. Aufl. Ärzte-Verlag, KölnGoogle Scholar
  10. 10.
    Cammu G, Troisi R, Cuomo O et al (2002) Anaesthetic management and outcome in right-lobe living liver-donor surgery. Eur J Anaesthesiol 19:93–98PubMedGoogle Scholar
  11. 11.
    Canver CC, Nichols RD (2000) Use of intraoperative hetastarch priming during coronary bypass. Chest 118:1616–1620PubMedCrossRefGoogle Scholar
  12. 12.
    Charles A, Purtill M, Dickinson S et al (2008) Albumin use guidelines and outcome in a surgical intensive care unit. Arch Surg 143:935–939PubMedCrossRefGoogle Scholar
  13. 13.
    Chien S, Sinclair DE, Dellenback J (1964) Effect of endotoxin on capillary permeability to macromolecules. Am J Physiol 207:518–522PubMedGoogle Scholar
  14. 14.
    Cope JT, Banks D, Mauney MC et al (1997) Intraoperative hetastarch infusion impairs hemostasis after cardiac surgery operations. Ann Thorac Surg 63:78–82PubMedCrossRefGoogle Scholar
  15. 15.
    Dubois MJ, Orellana-Jimenez C, Melot C et al (2006) Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med 34:2536–2540PubMedCrossRefGoogle Scholar
  16. 16.
    Duvoux C, Zanditenas D, Hezode C et al (2002) Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36:374–380PubMedCrossRefGoogle Scholar
  17. 17.
    Evans TW (2002) Review article: albumin as a drug - Biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 16 [Suppl 5]:6–11Google Scholar
  18. 18.
    Fan C, Phillips K, Sellin S (2005) Serum albumin: new thoughts on an old treatment. BCMJ 2(47):438–444Google Scholar
  19. 19.
    Fassio E, Terg R, Landeira G et al (1992) Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol 14:310–316PubMedCrossRefGoogle Scholar
  20. 20.
    Fernandez J, Monteagudo J, Bargallo X et al (2005) A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42:627–634PubMedCrossRefGoogle Scholar
  21. 21.
    Finfer S, Bellomo R, Boyce N et al (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256PubMedCrossRefGoogle Scholar
  22. 22.
    Fleck A, Raines G, Hawker F et al (1985) Increased vascular permeability. Major cause of hypoalbuminaemia in disease and injury. Lancet 1:781–783PubMedCrossRefGoogle Scholar
  23. 23.
    Garcia-Compean D, Blanc P, Larrey D et al (2002) Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 1:29–35PubMedGoogle Scholar
  24. 24.
    Gentilini P, Casini-Raggi V, diFiori G et al (1999) Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 30:639–645PubMedCrossRefGoogle Scholar
  25. 25.
    Gines A, Fernandez-Esparrach G, Monescillo A et al (1996) Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111:1002–1010PubMedCrossRefGoogle Scholar
  26. 26.
    Gines P, Tito L, Arroyo V et al (1988) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94:1493–1502PubMedGoogle Scholar
  27. 27.
    Green RS, Hall RI (2008) Con: starches are not preferable to albumin during cardiac surgery: a contrary opinion. J Cardiothorac Vasc Anesth 22:485–491PubMedCrossRefGoogle Scholar
  28. 28.
    Greenhalgh DG, Housinger TA, Kagan RJ et al (1995) Maintenance of serum albumin levels in pediatric burn patients: a prospective, randomized trial. J Trauma 39:67–73PubMedCrossRefGoogle Scholar
  29. 29.
    Guthrie RD Jr, Hines C Jr (1991) Use of intravenous albumin in the critically ill patient. Am Coll Gastroenterology 86:255–263Google Scholar
  30. 30. Scholar
  31. 31. Products/NewDrugApplicationsNDAs/UCM083138.pdfGoogle Scholar
  32. 32.
    Jardine LA, Jenkins-Manning S, Davies MW (2004) Albumin infusion for low serum albumin in preterm newborn infants. Cochrane Database Syst Rev 3, CD004208Google Scholar
  33. 33.
    Knutson JE, Deering JA, Hall FW et al (2000) Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery? Anesth Analg 90:801–807PubMedCrossRefGoogle Scholar
  34. 34.
    Kozek-Langenecker SA (2005) Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology 103:654–660PubMedCrossRefGoogle Scholar
  35. 35.
    Margarson MP, Soni N (1998) Serum albumin: touchstone or totem? Anaesthesia 53:789–803PubMedCrossRefGoogle Scholar
  36. 36.
    Martin GS, Moss M, Wheeler AP et al (2005) A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 33:1681–1687PubMedCrossRefGoogle Scholar
  37. 37.
    Mendez CM, McClain CJ, Marsano LS (2005) Albumin therapy in clinical practice. Nutr Clin Pract 20:314–320PubMedCrossRefGoogle Scholar
  38. 38.
    Moore KP, Aithal GP (2006) Guidelines on the management of ascites in cirrhosis. Gut 55 [Suppl VI]:1–12Google Scholar
  39. 39.
    Moore KP, Wong F, Gines P et al (2003) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38:258–266PubMedCrossRefGoogle Scholar
  40. 40.
    Moreau R, Durand F, Poynard T et al (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923–930PubMedCrossRefGoogle Scholar
  41. 41.
    Moreau R, Valla DC, Durand-Zaleski I et al (2006) Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver Int 26:46–54PubMedCrossRefGoogle Scholar
  42. 42.
    Mukhtar A, Aboulfetouh F, Obayah G et al (2009) The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesth Analg 109:924–930PubMedCrossRefGoogle Scholar
  43. 43.
    Oratz M, Rothschild MA, Schreiber SS (1970) Effect of dextran infusions on protein synthesis by hepatic microsomes. Am J Physiol 218:108–1112Google Scholar
  44. 44.
    Ortega R, Gines P, Uriz J et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948PubMedGoogle Scholar
  45. 45.
    Parving HH, Ranek L, Lassen NA (1977) Increased transcapillary escape rate of albumin in patients with cirrhosis of the liver. Scand J Clin Lab Invest 37:643–648PubMedCrossRefGoogle Scholar
  46. 46.
    Peltekian KM, Wong F, Liu PP et al (1997) Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol 92:394–399PubMedGoogle Scholar
  47. 47.
    Planas R, Gines P, Arroyo V et al (1990) Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 99:1736–1744PubMedGoogle Scholar
  48. 48.
    Quinlan GJ, Mumby S, Martin GS et al (2004) Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 32:755–759PubMedCrossRefGoogle Scholar
  49. 49.
    Reinhart K, Brunkhorst FM, Bone HG et al (2006) Diagnose und Therapie der Sepsis. S2-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI). Intensivmedizin 43:369–384CrossRefGoogle Scholar
  50. 50.
    Rimola A, Garcia-Tsao G, Navasa M et al (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 32:142–153PubMedCrossRefGoogle Scholar
  51. 51.
    Romanelli RG, La Villa G, Barletta G et al (2006) Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 12:1403–1407PubMedGoogle Scholar
  52. 52.
    Rossign N (1978) Intra- und extravascular distribution of albumin and immunoglobulin in man. Lymphology 11:38–142Google Scholar
  53. 53.
    SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service et al (2007) Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 357:874–884CrossRefGoogle Scholar
  54. 54.
    Salerno F, Badalamenti S, Lorenzano E et al (1991) Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 13:707–713PubMedCrossRefGoogle Scholar
  55. 55.
    Salerno F, Gerbes A, Gines P et al (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56:1310–1318PubMedGoogle Scholar
  56. 56.
    Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA (2003) Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 123:1853–1857PubMedCrossRefGoogle Scholar
  57. 57.
    So KW, Fok TF, Ng PC et al (1997) Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants. Arch Dis Child Fetal Neonatal 76:F43–F46CrossRefGoogle Scholar
  58. 58.
    Solanki P, Chawla A, Garg R et al (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18:152–156PubMedCrossRefGoogle Scholar
  59. 59.
    Sola-Vera J, Minana J, Ricart E et al (2003) Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 37:1147–1153PubMedCrossRefGoogle Scholar
  60. 60.
    Sort P, Navasa M, Arroyo V et al (1999) Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 342:403–409CrossRefGoogle Scholar
  61. 61.
    Standl T (2001) Albumin. In: Boldt J (Hrsg) Volumenersatztherapie. Thieme, Stuttgart, S 39–61Google Scholar
  62. 62.
    Stoddart PA, Rich P, Sury MRJ (1996) A comparison of 4.5% human albumin solution and Haemaccel in neonates undergoing major surgery. Paediatr Anaesth 6:103–106PubMedCrossRefGoogle Scholar
  63. 63.
    Sümpelmann R, Kretz FJ, Gäbler R et al (2008) Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement in children: preliminary results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS). Paediatr Anaesth 18:929–933PubMedCrossRefGoogle Scholar
  64. 64.
    University Health System Consortium (2000) Technology assessment: albumin, non-protein colloid and crystalloid solutions. Oak Book, IL, USAGoogle Scholar
  65. 65.
    Vincent JL (2006) Resuscitation using albumin in critically ill patients: research in patients at high risk of complications is now needed. BMJ 333:1029–1030PubMedCrossRefGoogle Scholar
  66. 66.
    Vincent JL, Wilkes MM, Navickis RJ (2003) Safety of human albumin – serious adverse events reported worldwide in 1998–2000. Br J Anaesth 91:625–630PubMedCrossRefGoogle Scholar
  67. 67.
    Wilkes MM, Navickis RJ (2001) Patient survival after human albumin administration – a meta-analysis of randomized controlled trials. Ann Intern Med 135:149–164PubMedGoogle Scholar
  68. 68.
    Wilkes MM, Navickis RJ, Sibbald WJ (2001) Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 72:527–533PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Klinik für Anästhesiologie und Operative IntensivmedizinKlinikum der Stadt LudwigshafenLudwigshafenDeutschland

Personalised recommendations